425: ARYA Sciences Acquisition Corp IV Announces Updated Investor Presentation for Adagio Medical Business Combination

ARYA Sciences Acquisition Corp IV provides an updated investor presentation regarding its business combination with Adagio Medical, Inc.

Summary

• ARYA Sciences Acquisition Corp IV (ARYA) has released an updated investor presentation, dated June 11, 2024, concerning its business combination with Adagio Medical, Inc.
• The presentation highlights Adagio's focus on cardiac arrhythmia treatments, specifically atrial fibrillation (AF) and ventricular tachycardia (VT).
• Adagio's technology aims to create durable, contiguous, and transmural lesions anywhere in the heart using ultra-low temperature cryoablation and pulsed field cryoablation.
• The company is targeting a \$3 billion catheter market with a near-term opportunity in the \$300 million VT ablation market.
• Adagio anticipates 2-3x segment growth in the VT ablation market with improved safety and effectiveness.
• The company also sees an opportunity for substantial share gain in the \$0.8 billion persistent AF segment, which is growing at 14% Y/Y.
• Key milestones include the commercial launch of vCLAS in Q1 2024, FULCRUM-VT pivotal study data readout expected in Q3 2025, and iCLAS PMA approval anticipated in Q1 2026.
• Adagio's management believes its technology can establish ablation as a first-line therapy for symptomatic AF patients, potentially leading to a 6-8x upside in ablations.
• The presentation includes forward-looking statements regarding future financial and operating performance, which are subject to risks and uncertainties.

Sentiment

Score: 7

Explanation: The document presents a positive outlook for Adagio Medical's future, highlighting its innovative technology and market opportunities. However, it also includes numerous disclaimers and risk factors, indicating a balanced perspective.

Positives

• Adagio Medical is targeting large, underserved markets in cardiac arrhythmia.
• The company has a unique portfolio supported by compelling clinical data.
• Adagio's technology has the potential to disrupt the market with commercial approvals in progress and pivotal data readouts expected.
• The company has leading inside investors, including Perceptive Advisors and RA Capital.
• The vCLAS CryoCure-VT clinical trial showed exceptional acute effectiveness and safety.
• The US FDA approved the FULCRUM-VT Pivotal IDE Supplement, increasing the number of study sites to 20 and subjects to 206.
• The iCLAS Cryoablation System is CE-Mark approved for the treatment of drug refractory, recurrent, symptomatic, Paroxysmal Atrial Fibrillation (PAF), Persistent Atrial Fibrillation (PsAF), and Atrial Flutter (AFL).

Negatives

• The presentation includes numerous disclaimers regarding forward-looking statements and the uncertainty of projections.
• The business combination is subject to various conditions and may not be completed.
• The company's expected cash runway only extends through 2025.
• The company has incurred net losses in every period to date and expects to continue to incur significant losses as it develops its business.

Risks

• The forward-looking statements are subject to risks, uncertainties, and other factors that may be beyond the control of ARYA, Adagio, or New Adagio.
• The inability to complete the Business Combination due to the failure to obtain approval of the shareholders of ARYA, to obtain financing to complete the Business Combination or to satisfy other conditions to closing.
• The amount of redemption requests made by ARYA's public shareholders.
• Delays in obtaining, adverse conditions in, or the inability to obtain regulatory approvals, or delays in completing regulatory reviews, required to complete the Business Combination.
• Adagio's ability to remain compliant with the covenants of its existing debt, including any convertible or bridge financing notes.
• New Adagio's ability to remain compliant with the covenants of, and other obligations under, the senior secured convertible notes that will be issued in connection with the closing of the Business Combination.
• The ability to recognize the anticipated benefits of the Business Combination, which may be affected by, among other things, competition, the ability of New Adagio to grow and manage growth profitably, maintain relationships with customers and suppliers and retain its management and key employees.
• The possibility that Adagio or New Adagio may be adversely affected by other economic, business, and/or competitive factors.
• Adagio's or New Adagio's use of proceeds, post-Business Combination fully diluted equity value or fully diluted enterprise value, expected pro forma cash, expected cash runway or funding gap, estimates of expenses and profitability.

Future Outlook

Adagio anticipates significant growth in the VT ablation and persistent AF markets, driven by improved technology and expanded indications. The company expects key milestones to be achieved in the next 18 months, including regulatory approvals and clinical data readouts.

Industry Context

The presentation positions Adagio Medical within the broader electrophysiology market, highlighting the competitive landscape and the potential for disruption with its innovative technologies. It emphasizes the need for improved long-term outcomes in atrial fibrillation treatment and the limitations of current ablation modalities.

Comparison to Industry Standards

• The presentation references several competitors in the cardiac ablation market, including Johnson & Johnson (Biosense Webster), Abbott, Medtronic, and Boston Scientific.
• It compares Adagio's technology to existing ablation modalities, such as radiofrequency (RF) ablation, cryoballoon ablation, and pulsed field ablation (PFA).
• The presentation cites clinical trials and registries, such as the MANIFEST-PF registry and the PULSED AF trial, to benchmark the outcomes of different ablation technologies.
• It also references the NHS cost-effectiveness model for technology comparisons to assess the value proposition of Adagio's products.

Stakeholder Impact

• Shareholders of ARYA will vote on the proposed business combination.
• The business combination could impact employees of both ARYA and Adagio Medical.
• The success of Adagio Medical's technology could benefit patients with cardiac arrhythmias.
• The business combination could affect the relationships between Adagio Medical and its suppliers and customers.

Next Steps

• Commercial launch of vCLAS in Q1 2024.
• Presentation of CryoCure-VT results at EHRA 2024.
• Initiation of post-market studies.
• FULCRUM-VT pivotal study data readout expected in Q3 2025.
• iCLAS PMA approval anticipated in Q1 2026.
• Estimated study enrollment completion for EU PARALELL Trial = Q4 2024 followed by 12-months follow-up
• CE-mark application/submission for EU PARALELL Trial expected to start Q2 2025

Key Dates